Ganjam V Kalpana

This inventor holds 7 USPTO granted patents and 1 published patent application. Top assignees: Albert Einstein College of Medicine, Columbia University. Active years: 1999-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ganjam V Kalpana. Retrieved from https://idiyas.com/inventor/ganjam-v-kalpana

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 1)

% Patents Active = 71.4

Average Co-Inventor Count = 1.8

ph-index = 4

Forward Citations = 36(Granted Patents)

Company Filing History:

5 out of 514

Albert Einstein College of Medicine

Years Active: 1999-2013

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8460635 - Fenretinide derivatives and uses thereof as therapeutic, diagnostic and imaging agents (2013-06-11),

2. 7846677 - Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1 (INI1)/hSNF5 (2010-12-07),

3. 7326416 - Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1(INI1)/hSNF5 (2008-02-05),

4. 6752994 - Insertional mutations in mycobacteria (2004-06-22),

5. 6566121 - Insertional mutations in mycobacteria (2003-05-20),

6. 6222024 - Nucleic acids encoding a human immunodeficiency virus type 1 (HIV-1) integrase interactor protein (INI-1) (2001-04-24),

7. 5872213 - Identification and characterization of a novel human protein designated (1999-02-16),

Title: Ganjam V Kalpana: Innovator in Therapeutic and Diagnostic Agents

Introduction

Ganjam V Kalpana is a notable inventor based in Yonkers, NY (US). He has made significant contributions to the fields of therapeutic and diagnostic agents, holding a total of 7 patents. His work focuses on innovative solutions for cancer treatment and HIV-1 inhibition.

Latest Patents

Among his latest patents is the development of Fenretinide derivatives and their uses as therapeutic, diagnostic, and imaging agents. This patent discloses synthetic peptidomimetic derivatives and phenyl group derivatives of Fenretinide (4-HPR), which are aimed at treating cancer and other diseases. Another significant patent involves the inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1 (INI1)/hSNF5. This patent provides peptides that inhibit HIV-1 production in human cells and outlines methods for preventing the spread of HIV-1.

Career Highlights

Ganjam V Kalpana has worked with prestigious institutions such as Albert Einstein College of Medicine and Columbia University. His research has led to advancements in understanding and combating serious health issues, particularly in the areas of cancer and viral infections.

Collaborations

He has collaborated with esteemed colleagues, including William R Jacobs, Jr. and Barry R Bloom, contributing to a rich environment of innovation and research.

Conclusion

Ganjam V Kalpana's work exemplifies the impact of innovative research in medicine. His patents and collaborations continue to pave the way for advancements in therapeutic and diagnostic technologies.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

1 patent pending: